The 31st Society for Neuro-Oncology Annual Meeting and Education Day will feature multiple Independent Supported Symposia (ISS) Sessions. Morning, lunchtime and evening sessions will be offered. Below is a list of the confirmed ISS sessions
Thursday, November 12, 2026
6:00 PM - 7:15 PM | Evening Session
Latest Data, Longer View: Treating NF1-Associated Symptomatic PN Across the Patient Journey
Location: Liberty Ballroom, Philadelphia Marriott Downtown
Speakers:
Alipi V. Bonm, MD, PhD, Swedish Neuroscience
Angela C. Hirbe, MD, PhD, Washington University School of Medicine
This session will explore the NF1-PN treatment journey through the perspectives of a patient advocate and experienced clinicians. Discussion will include new exploratory follow-up data extending up to 4 years and considerations for long-term therapy, evolving patient needs, and coordinated multidisciplinary care.
Supported by SpringWorks Therapeutics
"Experts in the Hot Seat”: Multidisciplinary Decision-making in Breast Cancer Brain Metastases in the ADC Era
Location: Independence Ballroom, Philadelphia Marriott Downtown
Registration: Click here.
Speakers:
Carey K. Anders, MD, Duke Cancer Institute, Duke University Health System
Manmeet S. Ahluwalia, MD, MBA, FASCO, Miami Cancer Institute
Christopher D. Lascola, MD, PHD, Brain Imaging & Analysis Center
Join this program, presented at the SNO Annual Meeting, for contemporary expert insights on applying current standards and interpreting emerging data for the multidisciplinary management of patients with breast cancer brain metastases.
Supported by Decera Clinical
Grant Supported by Daiichi Sankyo & Astrazenaca
Show Me the Data™: Turning Molecular Drivers Into Precision Care for CNS Tumors
Location: Room 108AB , Pennsylvania Convention Center
Registration: Click here.
An estimated 24,740 new primary brain and other central nervous system (CNS) tumors are expected to be diagnosed in the United States in 2026. Molecular classification is now central to diagnosis, prognosis, and treatment selection, with BRAF alterations and IDH mutations representing key actionable drivers across adult and pediatric CNS tumors. However, BRAF V600 mutations, non-V600 mutations, fusions, and splice variants are biologically and therapeutically distinct, requiring appropriate testing and interpretation to guide care. As targeted options expand, including BRAF/MEK combinations, type II RAF inhibitors, next-generation RAF inhibitors, and brain-penetrant IDH inhibitors, clinicians must be prepared to select molecular tests, assign alteration class, sequence targeted therapy with chemoradiation, and manage regimen-specific toxicities.
This CME/CE-certified Show Me the Data™ hybrid satellite symposium, held in conjunction with the 2026 Society for Neuro-Oncology (SNO) Annual Meeting, will provide practical, evidence-based guidance for managing BRAF- and IDH-altered primary CNS tumors. Through audience polling, faculty presentations, and panel discussion, participants will explore molecular testing for BRAF point mutations and fusions; IDH-directed therapy in grade 2 and higher-risk disease; treatment of newly diagnosed BRAF V600E adult high-grade glioma; emerging RAF strategies at recurrence; and alteration-matched therapy in pediatric low-grade glioma. The program will also address management of pyrexia, hepatotoxicity, and other toxicities that can affect treatment continuity, helping neuro-oncologists, medical oncologists, advanced practice providers, and the broader care team confidently match therapy to the relevant molecular driver.
Supported by Physicians' Educational Resource
This session is supported by an independent educational grant from Fore Biotherapeutics US Inc & Nuvation Bio Inc.
Friday, November 13, 2026
7:00 AM - 8:15 AM | Morning Session
Independent Supported Session
Location: Room 115C, Pennsylvania Convention Center
More information coming soon.
Supported by Alexion Pharmaceuticals Inc.
Key clinical endpoints in pediatric low-grade glioma: Limitations and implications of RAPNO-defined PFS and the clinical utility of TTNT and TFI endpoints to inform decision-making
Location: Michael A. Nutter Theatre, Pennsylvania Convention Center
Speaker:
Bradley Gampel, MD
This disease education symposium will explore considerations in evaluating treatment outcomes in pLGG, including the limitations & implications of RAPNO-defined progression-free survival (PFS) as well as the complementary endpoints of time to next treatment (TTNT) and treatment-free interval (TFI) to inform clinical decision-making
Supported by Day One Biopharmaceuticals.
Clinical Crossroads of IDH-Mutant Glioma Care: Navigating Real-World Challenges and Complexities
Location: Liberty Ballroom, Philadelphia Marriott Downtown
Registration: Click here.
Speakers:
Evanthia Galanis, MD, Mayo Clinic
Macarena de la Fuente, MD, Sylvester Comprehensive Cancer Center, University of Miami
Shawn Hervey-Jumper, MD, UCSF Weill Institute for Neurosciences
The management of IDH-mutant glioma is evolving rapidly from traditional toxic therapies toward targeted molecular treatments and earlier intervention. Let our distinguished faculty guide you on effective integration of novel targeted therapies into your practice and how to navigate complex clinical scenarios through enhanced multidisciplinary coordination.
Supported by Medscape.
This session is supported by an independent educational grant from Servier Pharmaceuticals
Implementing Systemic Therapy in H3 K27-Altered DMG: Practical Strategies to Optimize Post-Radiation Care
Location: Independence Ballroom, Philadelphia Marriott Downtown
Registration: Click here.
Speakers:
Stephen Bagley, MD
Carl Koschmann, MD
Karen Wright, MD
Supported by Decera Clinical.
Grant Supported by Jazz Pharmaceuticals.
Friday, November 13, 2026
6:00 PM - 7:15 PM | Evening Session
Beyond Anatomy: How Brain Chemistry is Changing Tumor Diagnosis, Progression, and Treatment Response
Location: Room 115AB, Pennsylvania Convention Center
Registration: Click here.
Speakers:
Patrick Wen, MD
Raymond Huang, MD PhD
Desmond Brown, MD PhD
Alexander Lin, PhD
Advances in brain tumor imaging and treatment are creating new opportunities to understand tumor biology and treatment response. This session will explore how metabolic information can complement conventional imaging, with a focus on IDH-mutant gliomas, 2-HG, LITT, and emerging applications in neuro-oncology.
Supported by BrainSpec.
Optimizing NF1 Tumor Management Across the Lifespan: Integrating Pain and Quality-of-Life Assessment into MEK Inhibitor and Surgical Decision-Making
Location: Room 108AB, Pennsylvania Convention Center
The education will address multidisciplinary management of neurofibromatosis type 1-associated plexiform neurofibromas across pediatric and adult care settings. Faculty will examine how patient-reported pain, functional impact, and quality of life should influence decisions to observe, initiate treatment, or escalate care. The program will also explore how MEK inhibitor therapy can be integrated with surgery, including patient selection and potential neoadjuvant, adjuvant, and salvage approaches. Finally, learners will review practical strategies for anticipating, monitoring, and managing MEK inhibitor-related toxicities while maintaining treatment intensity and avoiding unnecessary discontinuation.
Supported by CEConcepts.
Grant Supported by Alexion Pharmaceuticals Inc. & SpringWorks Therapeutics.
Tovorafenib 3-Year Update
Location: Michael A Nutter Theatre, Pennsylvania Convention Center
Registration: Click here.
Speaker :
Daniel Landi, MD
OJEMDA™ (tovorafenib): Type II RAF inhibitor for patients with BRAF-altered relapsed/refractory pediatric low-grade glioma (pLGG). OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)
Supported by Day One Biopharmaceuticals.
Accelerating Precision Neuro-Oncology with Integrated Methylation and Molecular Profiling
Location: Room 115C, Pennsylvania Convention Center
Registration: Click here.
Comprehensive molecular characterization has become essential for the accurate classification and management of CNS tumors. This industry-sponsored session will showcase how rapid, real-time Oxford Nanopore sequencing is enabling comprehensive tumor methylation profiling and molecular characterization, delivering insights faster than ever before. The session will explore the opportunities and challenges of implementing integrated molecular sequencing workflows and discuss the future of comprehensive molecular diagnostics in precision neuro-oncology.
Supported by Oxford Nanopore Technologies Inc.
Independent Supported Session
Location: Liberty Ballroom, Philadelphia Marriott Downtown
More information coming soon.
Supported by Telix Pharmaceuticals.
Saturday, November 14, 2026
7:00 AM - 8:15 AM | Morning Session
Understanding CNS Cancer Differently: Advancing Precision Diagnosis, Treatment, and Research
Location: Room 108AB, Pennsylvania Convention Center
Registration: Click here.
This symposium will explore evolving approaches to Leptomeningeal Metastases through a case-based clinical perspective, emerging therapeutic data, and the next generation of research designed to advance understanding of the disease. The program will begin with a real-world LM patient case, highlighting the complexities of diagnosis and management and how clinical approaches continue to evolve. The discussion will then turn to the development of new treatment options, including single-dose clinical data from the ReSPECT-LM program and an update on the ongoing multi-dose program. The symposium will conclude with a look toward the future of LM research through FORESEE 2.0, including its objectives and opportunities to generate new insights that may advance the diagnosis and treatment of patients with LM.
Supported by Cerenome (Formerly Plus Therapeutics).
CSF Liquid Biopsy in CNS Tumors: Diagnostic and Clinical Insights from a 1,600-Case Retrospective Analysis
Location: Michael A. Nutter Theatre, Pennsylvania Convention Center
Registration: Click here.
Speakers:
Chethan Bettegowda, MD, PhD, Johns Hopkins Medicine
Alexandra Miller, MD, NYU Langone Health
This symposium will present clinical evidence supporting the utility of CSF circulating tumor DNA (ctDNA) testing in CNS tumor care, followed by findings from more than 1,600 real-world cases.
Chetan Bettegowda, MD, PhD, Director of Neurosurgery at Johns Hopkins Medicine, will begin with a high-level review of the clinical utility of CSF ctDNA testing in CNS tumors.
Alexandra Miller, MD, co-director of NYU Langone’s Brain and Spine Tumor Center, will then present a retrospective analysis of Belay Diagnostics’ Summit™ 2.0, Ascent™, and Vantage™ tests across the United States over a 10-month period.
The session will address how molecular insights from CSF can inform diagnosis, guide therapeutic selection, and support assessment and monitoring of treatment response and disease progression.
Supported by Belay Diagnostics.
Advances in Diagnosis and Treatment of H3 K27M-Mutant Diffuse Glioma
Location: Liberty Ballroom ABC, Philadelphia Marriott Downtown
Speakers:
David A. Solomon, Stanford University
Nicole A. Shonka, University of Nebraska Medical Center
- Review the latest WHO CNS diagnostic criteria and molecular subtypes of diffuse midline glioma, H3 K27-altered.
- Discuss considerations in H3 K27 testing, including methods and potential diagnostic challenges,
- Describe the current treatment landscape and ongoing clinical research in H3 K27M-mutant diffuse midline glioma.
Supported by Jazz Pharmaceuticals.
Updated results from the INDIGO trial accompanied by a patient sharing their experience
Location: Room 103AB, Pennsylvania Convention Center
Speaker:
Dr. Rimas V. Lukas, Professor at Northwestern University
Provide the latest data updates including long term follow-up results from the INDIGO trial .
Supported by Servier Pharmaceuticals.